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Introduction 
Eosinophilic fasciitis is occasionally associated with 
morphea. However, cases of concurrent eosinophilic 
fasciitis and generalized morphea are rare. We herein 
describe a concurrent case of eosinophilic fasciitis 
and generalized morphea. 
 
Case Synopsis 
A 60-year-old man was referred to our hospital 
complaining of skin hardening and edema of his 
extremities. He had pruned plants 10 months prior to 
presentation. One week following the pruning, he 
experienced pain in his left shoulder and edema in 
the extremities. He noted limited range of 
movement in the joints. At initial presentation in his 
local hospital, laboratory examination showed an 
elevated eosinophil subset, and he was diagnosed as 
having eosinophilic fasciitis. He was treated with oral 
prednisolone (20mg/day). However, skin hardening 
and peripheral eosinophilia relapsed when the 
prednisolone was gradually decreased by a dose of 
2.5mg/day. Physical examination showed skin 
hardening of the upper and lower extremities 
(Figure 1A, B). The groove sign was observed in the 
Abstract 
A 60-year old man developed skin hardening and 
edema on his extremities. Although he had been 
treated with oral prednisolone at another hospital, 
skin stiffness relapsed during tapering of 
prednisolone. At the initial visit to our department, 
physical examination showed skin hardening of the 
extremities and also symmetric erythematous 
macules on the back. Histological examination 
revealed fasciitis on the forearm and morphea on the 
back. Eosinophilic fasciitis is occasionally associated 
with morphea. However, cases of concurrent 
eosinophilic fasciitis and generalized morphea are 
rare. In the present case, CD34 was differentially 
expressed in both lesions, suggesting eosinophilic 
fasciitis and morphea are separate diseases with 
different origin of mesenchymal cells. 
 
Figures 1. Clinical features showing induration of the skin of the 
A) upper, and B) lower limbs. C) Groove sign was observed on the 
forearm. D) Brownish erythema was present on the bilateral sides 
of the back. 
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forearm (Figure 1C). Neither sclerodactyly nor 
Raynaud phenomenon was recognized. Further 
examination revealed symmetric erythematous 
macules on the back, but without hardening of the 
skin (Figure 1D). 
Laboratory examination showed a slightly elevated 
eosinophil subset (7%) and increased C-reactive 
protein levels (1.14mg/dl). However, antinuclear 
antibody, anti-dsDNA and creatine kinase levels 
were normal. A biopsy specimen taken from the left 
forearm revealed thickened collagen bundles in the 
dermis and subcutaneous tissues with focal 
lymphocyte infiltrates in the subcutis and thickened 
fascia involvement (Figure 2A). There were 
perivascular and interstitial infiltrates of 
lymphocytes, plasma cells, and a few eosinophils in 
the thickened fascia (Figures 2B, C). The underlying 
skeletal muscle was not involved. Another specimen 
taken from the patient’s back showed that the 
collagen bundles of the reticular dermis were 
thickened (Figure 2D). A diagnosis of eosinophilic  
fasciitis/generalized morphea overlap was made 
based on the clinical, analytical, and 
histopathological findings. Immunohistochemistry 
results showed a focal loss of CD34 expression in the 
fascia of the area of eosinophilic fasciitis, whereas 
abundant expression of CD34 was observed in the 
morphea lesion (Figure 2E, F). The dose of 
prednisolone was escalated up to 40mg/day and 
thereafter gradually tapered every one or two 
months. Currently, the patient is controlled with 
15mg prednisolone daily, which is still being 
gradually tapered. 
 
Case Discussion 
Eosinophilic fasciitis is occasionally induced by 
vigorous exercise as well as trauma, leading to the 
hardening of the skin and limited range of 
movement in the joints. Eosinophilic fasciitis is often 
regarded to belong to the severe end of the morphea 
spectrum [1] and an association with morphea has 
been reported in 19-41% of eosinophilic fasciitis  
  
  
Figures 2. A) A biopsy specimen from the forearm shows fibrosis of deep dermis and subcutis, and thickened muscle fascia with 
inflammatory cell infiltrates. H&E, 40×. B, C) Higher magnification shows that cellular infiltrates in the thickened fascia are composed of 
lymphocytes, plasma cells, and eosinophils (arrow). H&E, 200×. 400×. D) A second biopsy from the back shows thickened collagen bundle 
with deposition of homogeneous materials in the whole dermis. H&E, 40×. E) CD34 expression is absent in the fascia of eosinophilic 
fasciitis (forearm), 200×. F) whereas it is abundant in the morphea (back). 400×. 
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patients [2-4]. In contrast, generalized morphea is 
rarely seen, and to our knowledge only seven cases 
of concurrent eosinophilic fasciitis and generalized 
morphea have been reported in the English 
literature [5-10]. The patient characteristics of these 
reported cases are shown in Table 1. The average 
age at occurrence was 47.1 years old and men were 
predominant (5:2 male to female ratio). In all cases, 
extremities, a common site of eosinophilic fasciitis, 
were involved. Generalized morphea occurred in the 
trunk in four cases. Eosinophilic fasciitis was 
diagnosed prior to generalized morphea in two 
cases. The onset period was between twelve months 
and six years. In all cases, treatment was started with 
prednisolone from small to moderate amounts. Two 
cases underwent additional treatment with 
immunosuppressive drugs. 
Although generalized morphea and eosinophilic 
fasciitis are believed to be different diseases, they are 
similar in presentation and are sometimes difficult to 
differentiate from each other. Previous studies 
showed that CD34 expression decreased or 
disappeared in the lesional skin of scleroderma, 
including morphea [11], which is inversely related 
with the extent of morphea [12]. CD34 is a marker of 
dermal dendritic cells and expression of CD34 and 
type I collagen suggest fibrocytes in the peripheral  
circulation. Fibrocytes are induced by transforming 
growth factor-β to express α-smooth muscle actin, a 
myofibroblastic property. A recent paper 
demonstrated a further decreased CD34 expression 
in the fascia of eosinophilic fasciitis, compared with 
morphea profunda [13], suggesting that the two 
diseases have different etiologies. We compared the 
local CD34 expression of biopsied tissue samples 
from different sites, which revealed that CD34 
expression disappeared in the fascia of eosinophilic 
fasciitis, whereas it was observed in the morphea 
lesion, consistent with previous reports. 
 
Conclusion 
Our case showed different expression of CD34 
between eosinophilic fasciitis and morphea lesions, 
suggests that both disorders possess separate 
phenotypes with different origin of mesenchymal 
cells. Alternatively, the possibility that CD 34 
expression simply reflects the intensity of skin 
fibrosis cannot be excluded. Further studies are 
needed to clarify the causative mechanisms of 
eosinophilic fasciitis and deep morphea. 
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Table 1. Seven cases of concurrent eosinophilic fasciitis and generalized morphea. 
Case  
Age 
Sex 
Involved site of 
eosinophilic fascilitis  
Involved site of 
generalized 
morphea 
Preceding 
onset Duration* Therapy  
1 [5] 25M Extremities, trunk, scalp Left thigh Unknown — Prednisolone
2 [6] 50F 
Chest, abdomen, breast, 
proximal portions of the 
arm and legs 
Upper extremities Generalized morphea 12Mo 
Prednisolone, etanercept 
methotrexate 
3 [7] 44F Forearms, legs 
Back, chest, 
abdomen, proximal 
extremities
Eosinophilic 
fasciitis 
12Mo Prednisolone  
4 [8] 66M Upper limbs, chest Tibialis anterior  Unknown  — Prednisolone 
5 [9] 61M extremities Abdomen, trunk Unknown — Prednisolone
6 [10] 24M Arms, legs, trunk Chest, upper back Eosinophilic fasciitis 6Yr 
Prednisolone, azathioprine, 
mycophenolate mofetil, 
cyclophosphamide, 
cyclosporine, rituximab    
Present 
case 60M Extremities  Back  Unknown  — Prednisolone 
* Mo-months; Yr-years. 
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